TBC1D20

Across TCGA pan-cancer cohorts, TBC1D20 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TBC1D20 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TBC1D20 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TBC1D20 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, UCEC, and KICH are the cancer types where TBC1D20 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.400	0.769	<.001	46	view →
UCEC	DFS	Median	II,III,IV	1.000	0.436	.011	28	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
LUSC	DFS	Median	All	0.198	0.712	.009	12	view →
BLCA	OS	Median	III,IV	0.052	0.582	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TBC1D20–HNSC (OS)

Open the HNSC breakdown →